Electromed, Inc. (ELMD) Q4 2024 Earnings Call Transcript Summary
Electromed, Inc. (ELMD) Q4 2024 Earnings Call Transcript Summary
Net income for the fiscal year was $5.2 million, a 62.7% increase from fiscal 2023, driven by robust revenue growth and effective expense management.The following is a summary of the Electromed, Inc. (ELMD) Q4 2024 Earnings Call Transcript:
以下是Electromed, Inc. (ELMD) 2024年第四季度業績會議記錄總結：
Financial Performance:
金融業績：
Electromed reported record Q4 revenue of $14.8 million, a 9% year-over-year increase, and record annual revenue of $54.7 million, a 14% increase from the previous fiscal year.
Operating income for Q4 and the full fiscal year reached record highs of $2.3 million and $6.6 million, respectively.
Net income for the fiscal year was $5.2 million, a 62.7% increase from fiscal 2023, driven by robust revenue growth and effective expense management.
Electromed報告2024年第四季度營業收入創紀錄，爲1480萬美元，同比增長9％，全年營業收入也創下5470萬美元的歷史新高，比上一財年增長14％。
第四季度和整個財年的營業收入分別達到了230萬美元和660萬美元的歷史最高記錄。
本財年的淨利潤爲520萬美元，比2023財年增長了62.7％，得益於強勁的營業收入增長和有效的費用管理。
Business Progress:
業務進展：
Electromed expanded its sales team, ending the year with 53 sales reps and planning to increase to 57 by the end of fiscal year 2025.
Introduced SmartVest Clearway in the hospital market, seeing a 22% growth.
Launched SmartAdvantage and SmartNotes to support clinics and provide ongoing patient monitoring.
Improved inventory management, achieving zero back orders by the end of Q4.
Named one of the fastest-growing public companies in Minnesota, highlighting strong operational execution.
Electromed擴大了銷售團隊，年末共有53名銷售代表，並計劃在2025財年年底前增加至57名。
在醫院市場推出了SmartVest Clearway，並實現了22％的增長。
推出SmartAdvantage和SmartNotes，以支持診所並提供持續的患者監測。
改善庫存管理，到第四季度末實現零備貨訂單。
被評爲明尼蘇達州增長最快的上市公司之一，突顯了強大的運營執行力。
Opportunities:
機會：
Plans to increase the annual revenue per sales rep to between $900,000 and $1 million in fiscal year 2025.
Continued investment in market development for bronchiectasis awareness and education.
計劃在2025財年將銷售代表每年的營業收入增加至90萬美元至100萬美元之間。
持續投資於支氣管擴張症意識和教育的市場開發。
Risks:
風險：
The expiration of the CMS waiver could impact revenue streams, although this risk was successfully mitigated in Q4.
CMS豁免的到期可能會影響收入流，儘管這一風險在第四季度成功得到了緩解。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
